DXCM : NASDAQ : Health Care
$73.2 | %
Today's Range: 72.13 - 74.49
Avg. Daily Volume: 1160400.0
08/18/17 - 4:00 PM ET

Financial Analysis


DEXCOM INC's gross profit margin for the second quarter of its fiscal year 2017 has increased when compared to the same period a year ago. Sales and net income have grown, and although the growth in revenues has outpaced the average competitor within the industry, the net income growth has not. DEXCOM INC is extremely liquid. Currently, the Quick Ratio is 5.69 which clearly shows the ability to cover any short-term cash needs. The company's liquidity has increased from the same period last year.

At the same time, stockholders' equity ("net worth") has greatly increased by 43.54% from the same quarter last year. Overall, the key liquidity measurements indicate that the company is very unlikely to face financial difficulties in the near future.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. To learn more visit www.TheStreetRatings.com.



Income Statement Q2 FY17 Q2 FY16
Net Sales ($mil)170.6137.3
EBITDA ($mil)-9.7-16.2
EBIT ($mil)-13.6-20.1
Net Income ($mil)2.9-20.2


Balance Sheet Q2 FY17 Q2 FY16
Cash & Equiv. ($mil)496.6115.6
Total Assets ($mil)795.6332.8
Total Debt ($mil)327.26.0
Equity ($mil)353.7246.4


Profitability Q2 FY17 Q2 FY16
Gross Profit Margin71.1665.11
EBITDA Margin-5.68-11.79
Operating Margin-7.97-14.64
Sales Turnover0.81.47
Return on Assets-8.16-24.15
Return on Equity-18.37-32.62
Debt Q2 FY17 Q2 FY16
Current Ratio6.253.26
Debt/Capital0.480.02
Interest Expense3.10.1
Interest Coverage-4.39-201.0


Share Data Q2 FY17 Q2 FY16
Shares outstanding (mil)86.583.8
Div / share0.00.0
EPS0.03-0.24
Book value / share4.092.94
Institutional Own % n/a n/a
Avg Daily Volume1167395.01012499.0

Valuation


HOLD. This stock’s P/E ratio is negative, making its value useless in the assessment of premium or discount valuation, only displaying that the company has negative earnings per share. For additional comparison, its price-to-book ratio of 17.80 indicates a significant premium versus the S&P 500 average of 3.02 and a significant premium versus the industry average of 4.79. The price-to-sales ratio is well above both the S&P 500 average and the industry average, indicating a premium. Upon assessment of these and other key valuation criteria, DEXCOM INC seems to be trading at a premium to investment alternatives within the industry.


Price/Earnings
1 2 3 4 5
premium   discount
  Price/Cash Flow
1 2 3 4 5
premium   discount
DXCM NM Peers 47.77   DXCM 122.19 Peers 37.41

Neutral. The absence of a valid P/E ratio happens when a stock can not be valued on the basis of a negative stream of earnings.

DXCM's P/E is negative making this valuation measure meaningless.

 

Premium. The P/CF ratio, a stock’s price divided by the company's cash flow from operations, is useful for comparing companies with different capital requirements or financing structures.

DXCM is trading at a significant premium to its peers.

 
Price/Projected
Earnings
1 2 3 4 5
premium   discount
  Price to
Earnings/Growth
1 2 3 4 5
premium   discount
DXCM NM Peers 32.84   DXCM NA Peers 1.00

Neutral. The absence of a valid price-to-projected earnings ratio happens when a stock can not be valued on the basis of a negative expected future earnings.

DXCM's ratio is negative making this valuation measure meaningless.

 

Neutral. The PEG ratio is the stock’s P/E divided by the consensus estimate of long-term earnings growth. Faster growth can justify higher price multiples.

Ratio not available.

 
Price/Book
1 2 3 4 5
premium   discount
  Earnings Growth
1 2 3 4 5
lower   higher
DXCM 17.80 Peers 4.79   DXCM 21.43 Peers 34.43

Premium. A higher price-to-book ratio makes a stock less attractive to investors seeking stocks with lower market values per dollar of equity on the balance sheet.

DXCM is trading at a significant premium to its peers.

 

Lower. Elevated earnings growth rates can lead to capital appreciation and justify higher price-to-earnings ratios.

However, DXCM is expected to significantly trail its peers on the basis of its earnings growth rate.

 
Price/Sales
1 2 3 4 5
premium   discount
  Sales Growth
1 2 3 4 5
premium   discount
DXCM 9.95 Peers 5.07   DXCM 29.25 Peers 11.44

Premium. In the absence of P/E and P/B multiples, the price-to-sales ratio can display the value investors are placing on each dollar of sales.

DXCM is trading at a significant premium to its industry.

 

Higher. A sales growth rate that exceeds the industry implies that a company is gaining market share.

DXCM has a sales growth rate that significantly exceeds its peers.

 

 

Latest Stock Upgrades/Downgrades